open access

Vol 72, No 2 (2022)
Review paper
Published online: 2022-02-11
Get Citation

Selected platinum complexes in standard and modern anti-cancer therapies

Anna Kopacz-Bednarska1, Teodora Król1
DOI: 10.5603/NJO.a2022.0011
·
Nowotwory. Journal of Oncology 2022;72(2):96-105.
Affiliations
  1. Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Kielce, Poland

open access

Vol 72, No 2 (2022)
Review article
Published online: 2022-02-11

Abstract

The constantly observed increase in the number of cancer cases inspires research aimed at searching for new compo­unds with anti-cancer potential. In recent years, much research has focused on platinum complexes, especially their anti-cancer properties. Platinum derivatives are characterized by high cytotoxic activity against many types of cancer cells. However, among the numerous developed complexes, only cisplatin, carboplatin and oxaliplatin have found wide application in chemotherapeutic treatment. Nedaplatin, lobaplatin and heptaplatin have also gained recognition, and have been implemented in oncological therapy in Japan, China and Korea. Some of the platinum complexes are still at the stage of pre-clinical and clinical trials. The aim of the research conducted today is to search for platinum compo­unds that show high pharmacological effectiveness, with clearly limited side effects. In future therapeutic strategies, the possibility of using platinum complexes in conjunction with other chemotherapeutic compounds is being considered, which may contribute to increasing the efficacy of anti-cancer therapy.

Abstract

The constantly observed increase in the number of cancer cases inspires research aimed at searching for new compo­unds with anti-cancer potential. In recent years, much research has focused on platinum complexes, especially their anti-cancer properties. Platinum derivatives are characterized by high cytotoxic activity against many types of cancer cells. However, among the numerous developed complexes, only cisplatin, carboplatin and oxaliplatin have found wide application in chemotherapeutic treatment. Nedaplatin, lobaplatin and heptaplatin have also gained recognition, and have been implemented in oncological therapy in Japan, China and Korea. Some of the platinum complexes are still at the stage of pre-clinical and clinical trials. The aim of the research conducted today is to search for platinum compo­unds that show high pharmacological effectiveness, with clearly limited side effects. In future therapeutic strategies, the possibility of using platinum complexes in conjunction with other chemotherapeutic compounds is being considered, which may contribute to increasing the efficacy of anti-cancer therapy.

Get Citation

Keywords

cisplatin; platinum complexes; anticancer drugs; chemotherapy

About this article
Title

Selected platinum complexes in standard and modern anti-cancer therapies

Journal

Nowotwory. Journal of Oncology

Issue

Vol 72, No 2 (2022)

Article type

Review paper

Pages

96-105

Published online

2022-02-11

Page views

456

Article views/downloads

90

DOI

10.5603/NJO.a2022.0011

Bibliographic record

Nowotwory. Journal of Oncology 2022;72(2):96-105.

Keywords

cisplatin
platinum complexes
anticancer drugs
chemotherapy

Authors

Anna Kopacz-Bednarska
Teodora Król

References (100)
  1. Wojciechowska U, Czaderny K, Ciuba A. Cancer in Poland in 2016. Polish National Cancer Registry Department of Epidemiology and Cancer Prevention. 2018: 1–98.
  2. Didkowska J, Wojciechowska U, Czaderny K. Cancer in Poland in 2017. Polish National Cancer Registry Department of Epidemiology and Cancer Prevention. 2019 : 1–96.
  3. Strzelecki Z. Prognozy rozwoju chorób nowotworowych w Polsce. In: Potrykowska A, Strzelecki Z, Szymborski J. et al. ed. Zachorowalność i umieralność na nowotwory a sytuacja demograficzna Polski. Zakład Wydawnictw Statystycznych, Warszawa 2014: 7–17.
  4. Wiszniewska M, Lipinska-Ojrzanowska A, Witkowska A, et al. Occupational cancers – Epidemiology and certification. Medycyna Pracy. 2017.
  5. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010; 6(12): 1863–1881.
  6. Soung N, Kim B. Psychological stress and cancer. J Anal Sci Technol. 2015; 6(1).
  7. Dai S, Mo Y, Wang Y, et al. Chronic Stress Promotes Cancer Development. Front Oncol. 2020; 10: 1492.
  8. Key TJ, Schatzkin A, Willett WC, et al. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004; 7(1A): 187–200.
  9. Tandon M, Siddique RA, Singh NK, et al. Anti-cancer diet: reviewing the role of nutrition in cancer prevention. Curr Top Nutraceut Res. 2008; 6(2): 67–82.
  10. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Front Pharmacol. 2018; 9: 245.
  11. Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019; 54(2): 407–419.
  12. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019; 2: 141–160.
  13. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020; 21(9).
  14. Dai Z, Wang Z. Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action. Molecules. 2020; 25(21).
  15. Śliwińska-Hill U, Szumełda M. Biologiczne podstawy terapii przeciwnowotworowej z zastosowaniem leków platynowych. Oddziaływanie z cytochromem c. Nowotwory. Journal of Oncology. 2016; 66(2): 136–150.
  16. Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019; 53(2): 148–158.
  17. Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3(1): 1351–1371.
  18. Tchounwou PB, Dasari S, Noubissi FK, et al. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740: 364–378.
  19. Gregory MT, Park GaY, Johnstone TC, et al. Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res. 2014; 34(1): 471–476.
  20. Velma V, Dasari SR, Tchounwou PB. Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark Insights. 2016; 11: 113–121.
  21. Konac E, Varol N, Kiliccioglu I, et al. Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett. 2015; 10(1): 560–564.
  22. Perkhofer L, Berger AW, Beutel AK, et al. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer. 2019; 19(1): 990.
  23. Yeku O, Russo AL, Lee H, et al. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med. 2020; 18(1): 350.
  24. Ciarimboli G, Ciarimboli G. Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo). 2012; 2012(1): 473829–550.
  25. Łacko A, Hudziec P, Mazur G. Porównanie parametrów farmakologicznych i klinicznych cisplatyny i karboplatyny w leczeniu guzów litych. Nowotwory J Oncol. 2000; 50(6): 609.
  26. Aldossary S. Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. Biomed Pharmacol J. 2019; 12(1): 07–15.
  27. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9): 994–1007.
  28. Volarevic V, Djokovic B, Jankovic MG, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019; 26(1): 25.
  29. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol. 2002; 13(4): 858–865.
  30. Jiang M, Yi X, Hsu S, et al. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol. 2004; 287(6): F1140–F1147.
  31. Rathinam R, Ghosh S, Neumann WL, et al. Cisplatin-induced apoptosis in auditory, renal, and neuronal cells is associated with nitration and downregulation of LMO4. Cell Death Discov. 2015; 1.
  32. Wang P, Cui J, Wen J, et al. Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett. 2016; 12(6): 4605–4612.
  33. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31(15): 1869–1883.
  34. Sarin N, Engel F, Kalayda GV, et al. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One. 2017; 12(7): e0181081.
  35. Bahar E, Kim JY, Kim HS, et al. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression. Int J Mol Sci. 2020; 21(20).
  36. Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010; 39(35): 8113–8127.
  37. Subocz M, Popławska B, Bielawska A, et al. Pochodne platyny w chemioterapii chorób nowotworowych. Annal Acad Med Siles. 2011; 65(4): 70–76.
  38. Ciancetta A, Coletti C, Marrone A, et al. Activation of carboplatin by chloride ions: a theoretical investigation. Theor Chem Acc. 2011; 129(6): 757–769.
  39. Sousa G, Wlodarczyk S, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz J Pharm Sci. 2014; 50(4): 693–701.
  40. Pavelka M, Lucas MF, Russo N. On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry. 2007; 13(36): 10108–10116.
  41. Werengowska KM, Wiśniewski M, Terzyk AP, et al. Chemiczne aspekty celowanej terapii przeciwnowotworowej II. Połączenia nośnik-lek. Wiad Chem. 2012; 66(7-8): 637–670.
  42. Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. World J Clin Oncol. 2017; 8(4): 329–335.
  43. Trynda-Lemiesz L, Śliwińska-Hill U. Kompleksy metali w terapii nowotworowej. Teraźniejszość i przyszłość. Nowotwory J Oncol. 2011; 61(5): 465–474.
  44. Huang CY, Cheng M, Lee NR, et al. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. Int J Environ Res Public Health. 2020; 17(7).
  45. Rosca L, Robert-Boire V, Delisle JF, et al. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas. Pediatr Blood Cancer. 2018; 65(11): e27351.
  46. Yu KD, Ye FG, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(9): 1390–1396.
  47. Mielcarek P, Majdak E, Krasińska E, et al. Comparison of quality of life in patients with advanced ovarian cancer treated with intravenous paclitaxel and carboplatin versus cyclophosphamide and cisplatin as first line chemotherapy – a preliminary report. Nowotwory J Oncol. 2002; 52(1): 33–36.
  48. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1): 18–25.
  49. Kozakiewicz K, Kaczmarczyk M. Cisplatyna – lek z przypadku. Curr Gynecol Oncol. 2012; 10(2): 131–140.
  50. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004; 91(11): 1931–1946.
  51. Seetharam Rn, Sood A, Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. Ecancermedicalscience. 2009; 3: 153.
  52. Tournigand C, André T, Bonnetain F, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23): 2343–2351.
  53. Saeki H, Emi Y, Oki E, et al. Kyushu Study group of Clinical Cancer (KSCC). Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. BMC Cancer. 2018; 18(1): 57.
  54. Xiao C, Qian J, Zheng Y, et al. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. Medicine (Baltimore). 2019; 98(20): e15696.
  55. Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res. 2013; 5: 67–76.
  56. Mabuchi S, Kimura T. Nedaplatin: a radiosensitizing agent for patients with cervical cancer. Chemother Res Pract. 2011; 2011: 963159.
  57. Chikazawa K, Netsu S, Imai K, et al. Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin. Taiwan J Obstet Gynecol. 2020; 59(4): 546–550.
  58. Kenmotsu Y, Oshita F, Sugiura M, et al. Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung. Anticancer Res. 2012; 32(4): 1453–1456.
  59. Ge Li, Li N, Yuan GW, et al. Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. Am J Cancer Res. 2018; 8(6): 1074–1082.
  60. Zhu H, Ge X, Lu Y, et al. Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. Oncol Lett. 2019; 17(1): 594–602.
  61. Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy - an update from drug design perspective. Drug Des Devel Ther. 2017; 11: 599–616.
  62. Hua S, Kong X, Chen B, et al. Anticancer Mechanism of Lobaplatin as Monotherapy and in Combination with Paclitaxel in Human Gastric Cancer. Curr Mol Pharmacol. 2018; 11(4): 316–325.
  63. Zhou NN, Zhao YY, Zhai LZ, et al. The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer. J Cancer. 2018; 9(13): 2232–2236.
  64. Yin CY, Lin XL, Tian L, et al. Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis. World J Gastroenterol. 2014; 20(46): 17426–17433.
  65. Shan L, Bai B, Lv Y, et al. Lobaplatin suppresses proliferation and peritoneal metastasis of colorectal cancer in a preclinical model. Biomed Pharmacother. 2018; 108: 486–491.
  66. Ma D, Li S, Cui Y, et al. Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway. Oncol Lett. 2018; 15(5): 6211–6216.
  67. Pan S, Sun Y, Sui D, et al. Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018; 102: 567–574.
  68. Zhou Z, Jiang H, Xia J, et al. Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo. Int J Oncol. 2020; 57(3): 697–706.
  69. Welink J, Boven E, Vermorken JB, et al. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res. 1999; 5(9): 2349–2358.
  70. Zhang HY, Liu YR, Li W, et al. Condensations of single DNA molecules induced by heptaplatin and its chiral isomer. AIP Advances. 2014; 4(8): 087128.
  71. Kang X, Xiao HH, Song HQ, et al. Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med. 2015; 12(4): 362–374.
  72. Choi CH, Cha YJ, An CS, et al. Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein. Cancer Cell Int. 2004; 4(1): 6.
  73. Lee WS, Lee GW, Kim HW, et al. A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer. Cancer Res Treat. 2005; 37(4): 208–211.
  74. Lee KH, Hyun MS, Kim HK, et al. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009; 41(1): 12–18.
  75. Brown SD, Trotter KD, Sutcliffe OB, et al. Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity. Dalton Trans. 2012; 41(37): 11330–11339.
  76. Tang CH, Parham C, Shocron E, et al. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol. 2011; 67(6): 1389–1400.
  77. www.clinicaltrials.gov.
  78. Monroe JD, Hruska HL, Ruggles HK, et al. Anti-cancer characteristics and ototoxicity of platinum(II) amine complexes with only one leaving ligand. PLoS One. 2018; 13(3): e0192505.
  79. Park GaY, Wilson JJ, Song Y, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012; 109(30): 11987–11992.
  80. Hucke A, Park GaY, Bauer OB, et al. Interaction of the New Monofunctional Anticancer Agent Phenanthriplatin With Transporters for Organic Cations. Front Chem. 2018; 6: 180.
  81. Facchetti G, Rimoldi I. Anticancer platinum(II) complexes bearing N-heterocycle rings. Bioorg Med Chem Lett. 2019; 29(11): 1257–1263.
  82. McDevitt CE, Yglesias MV, Mroz AM, et al. Monofunctional platinum(II) compounds and nucleolar stress: is phenanthriplatin unique? J Biol Inorg Chem. 2019; 24(6): 899–908.
  83. Monroe JD, Moolani SA, Irihamye EN, et al. RNA-Seq Analysis of Cisplatin and the Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines. Cells. 2020; 9(12).
  84. Kaspárková J, Nováková O, Vrána O, et al. Molecular aspects of antitumor effects of a new platinum(IV) drug. Mol Pharmacol. 2006; 70(5): 1708–1719.
  85. Olszewski U, Ach F, Ulsperger E, et al. In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. Met Based Drugs. 2009; 2009: 348916.
  86. Halámiková A, Heringová P, Kaspárková J, et al. Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine. J Inorg Biochem. 2008; 102(5-6): 1077–1089.
  87. Cerón-Carrasco JP. Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs. Int J Mol Sci. 2020; 21(13).
  88. Klameth L, Rath B, Hamilton G. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. J Cancer. 2017; 8(10): 1733–1743.
  89. Allocati N, Masulli M, Di Ilio C, et al. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018; 7(1): 8.
  90. Li S, Li C, Jin S, et al. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. Biomaterials. 2017; 144: 119–129.
  91. Liu D, He C, Wang AZ, et al. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine. 2013; 8: 3309–3319.
  92. Zisman N, Dos Santos N, Johnstone S, et al. Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations. Chemother Res Pract. 2011; 2011: 213848.
  93. Jehn CF, Boulikas T, Kourvetaris A, et al. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res. 2007; 27(1A): 471–475.
  94. Fantini M, Gianni L, Santelmo C, et al. Lipoplatin Treatment in Lung and Breast Cancer. Chemother Res Pract. 2011; 2011: 1–7.
  95. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012; 2012: 581363.
  96. Weiss-Gradzińska W, Krzempek W, Trynda-Lemiesz L. Mechanizm oporności na leki platynowe oraz strategie pokonywania tego zjawiska. Wiad Chem. 2013; 67: 11–12.
  97. Manzotti C, Pratesi G, Menta E, et al. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res. 2000; 6(7): 2626–2634.
  98. Salerno D, Beretta GL, Zanchetta G, et al. Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophys J. 2016; 110(10): 2151–2161.
  99. Sessa C, Capri G, Gianni L, et al. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol. 2000; 11(8): 977–983.
  100. Kasparkova J, Zehnulova J, Farrell N, et al. DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464. J Biol Chem. 2002; 277(50): 48076–48086.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl